Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flumatinib vs imatinib in newly diagnosed chronic phase CML
CTR20140513Phase 3Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of Flumatinib in chronic myelogenous leukemia (CML), sponsored by Hengrui Therapeutics. Started Aug 2014; status: completed.
02
Drugs
Flumatinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on CTR20140513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20140513.